Literature DB >> 20138341

The effect of epigenetic therapy on congenital neurogenic bladders--a pilot study.

Steve J Hodges1, James J Yoo, Nilamadhab Mishra, Anthony Atala.   

Abstract

OBJECTIVES: To demonstrate that human smooth muscle cells derived from neurogenic bladders produce more collagen in vitro than smooth muscle cells derived from normal bladders, and that epigenetic therapy may normalize this increased collagen production.
METHODS: Human smooth muscle cells from normal (n = 3) and neurogenic bladders (n = 3) were cultured in normal culture media and at different concentrations of the histone deacetylase inhibitors trichostatin A, valproic acid, and the DNA methylation inhibitor 5-azacytidine (5-aza). Collagen type I and III gene expression was measured using real-time quantitative reverse transcription-polymerase chain reaction after varying doses of drug exposure. Cell viability was measured using trypan blue.
RESULTS: The smooth muscle cells from neurogenic bladders released significantly more collagen than the normal bladder cells (mean 4.1 vs 1.8 microg/mL in control media) when grown in normal conditions. Treatment with trichostatin A at 50 ng/mL decreased the collagen level in cells from neurogenic bladders to almost normal levels (2.1 microg/mL). In addition, valproic acid treatment decreased collagen types I and III gene expression relative to controls, with maximal effect at 300 mg/mL. These treatments had little effect on cell viability.
CONCLUSIONS: Histone deacetylase inhibitors decreased collagen production of smooth muscle cells from neurogenic bladders in vitro. These agents may be a means of effectively preventing bladder fibrosis in patients with this condition. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20138341      PMCID: PMC2860424          DOI: 10.1016/j.urology.2009.11.022

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  20 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Antimuscarinics for treatment of overactive bladder.

Authors:  Karl-Erik Andersson
Journal:  Lancet Neurol       Date:  2004-01       Impact factor: 44.182

Review 3.  Electrical stimulation for the treatment of bladder dysfunction: current status and future possibilities.

Authors:  Saso Jezernik; Michael Craggs; Warren M Grill; Graham Creasey; Nico J M Rijkhoff
Journal:  Neurol Res       Date:  2002-07       Impact factor: 2.448

4.  Trichostatin A, lead compound for development of antifibrogenic drugs.

Authors:  K Rombouts; T Niki; A Wielant; K Hellemans; A Geerts
Journal:  Acta Gastroenterol Belg       Date:  2001 Jul-Sep       Impact factor: 1.316

Review 5.  Histone deacetylase inhibitors: understanding a new wave of anticancer agents.

Authors:  Ana Villar-Garea; Manel Esteller
Journal:  Int J Cancer       Date:  2004-11-01       Impact factor: 7.396

Review 6.  Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy.

Authors:  Wolfgang Löscher
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

7.  The value of urodynamic testing in the management of neonates with myelodysplasia: a prospective study.

Authors:  A A Sidi; D D Dykstra; R Gonzalez
Journal:  J Urol       Date:  1986-01       Impact factor: 7.450

8.  Phenylbutyrate decreases type I collagen production in human lung fibroblasts.

Authors:  David C Rishikof; Dennis A Ricupero; Hanqiao Liu; Ronald H Goldstein
Journal:  J Cell Biochem       Date:  2004-03-01       Impact factor: 4.429

9.  Phenotypic and functional characterization of in vivo tissue engineered smooth muscle from normal and pathological bladders.

Authors:  Jin-Yao Lai; Cheol Yong Yoon; James J Yoo; Tina Wulf; Anthony Atala
Journal:  J Urol       Date:  2002-10       Impact factor: 7.450

Review 10.  Emerging role of botulinum toxin in the treatment of neurogenic and non-neurogenic voiding dysfunction.

Authors:  Christopher P Smith; George T Somogyi; Michael B Chancellor
Journal:  Curr Urol Rep       Date:  2002-10       Impact factor: 2.862

View more
  4 in total

Review 1.  The Genetic Basis of Peyronie Disease: A Review.

Authors:  Amin S Herati; Alexander W Pastuszak
Journal:  Sex Med Rev       Date:  2016-01-08

Review 2.  Epigenetic regulation of smooth muscle cell plasticity.

Authors:  Renjing Liu; Kristen L Leslie; Kathleen A Martin
Journal:  Biochim Biophys Acta       Date:  2014-06-15

3.  Inhibition of histone deacetylase 2 mitigates profibrotic TGF-β1 responses in fibroblasts derived from Peyronie's plaque.

Authors:  Ji-Kan Ryu; Woo-Jean Kim; Min-Ji Choi; Jin-Mi Park; Kang-Moon Song; Mi-Hye Kwon; Nando-Dulal Das; Ki-Dong Kwon; Dulguun Batbold; Guo-Nan Yin; Jun-Kyu Suh
Journal:  Asian J Androl       Date:  2013-06-17       Impact factor: 3.285

4.  Phenotypic switching induced by damaged matrix is associated with DNA methyltransferase 3A (DNMT3A) activity and nuclear localization in smooth muscle cells (SMC).

Authors:  Jia-Xin Jiang; Karen J Aitken; Chris Sotiropoulos; Chris Sotiropolous; Tyler Kirwan; Trupti Panchal; Nicole Zhang; Shuye Pu; Shoshana Wodak; Cornelia Tolg; Darius J Bägli
Journal:  PLoS One       Date:  2013-08-07       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.